Early Alzheimer's Evaluation in Cuba for Michigan Families

Early evaluation is one of the most powerful tools in Alzheimer's care. The Alzheimer's Association emphasizes that early and accurate diagnosis can help patients explore treatment options, maintain independence longer, participate in clinical trials, and plan for the future while they still can. In the United States, however, comprehensive early evaluation is often limited by insurance coverage and appointment availability.

Cuba's early evaluation program is designed for patients with mild cognitive impairment (MCI) or early-stage Alzheimer's disease. The evaluation includes detailed neuropsychological testing to distinguish normal aging from MCI and early Alzheimer's, brain MRI to assess hippocampal atrophy and other early markers, blood work to rule out reversible causes of cognitive decline, and a comprehensive multidisciplinary team assessment.

Following the evaluation, the medical team provides a personalized treatment plan that may include NeuroEPO research (available for mild cognitive impairment and mild Alzheimer's), intensive cognitive rehabilitation (most effective when started early, when neuroplasticity is greatest), pharmacological management, and caregiver education. Early intervention offers the best opportunity to slow cognitive decline and maintain function — though no treatment currently cures Alzheimer's, and individual outcomes vary.